Olaparib is set to become a standard treatment option for advanced prostate cancer patients whose tumours harbour certain genetic alterations.
Study results presented at ESMO congress in Barcelona shows good response to olaparib compared to other hormonal agents in this sub-group of patients.
1. ESMO European Society of Medical Oncology Annual Conference 2019. Barcelona. Olaparib Outperforms Enzalutamide or Abiraterone Acetate in Men with mCRPC and HRR Alterations.
Disclaimer: Please note- This blog is NOT medical advice. This blog is purely for information only. See your own doctor to discuss concerns and options relevant for you.
Acknowledgement: Copyright of Slides: Authors and ESMO